SCFAs may regulate T2DM pathogenesis by binding to GPR43 receptors on colonic L cells, promoting glucagon-like peptide-1 (GLP-1) production, and activating GPR41 to increase peptide YY (PYY) secretion. This evidence concerns the gene GCG and type 2 diabetes mellitus.